Tag
Sanofi agreed to buy Dynavax Technologies for about US$2.2 billion to expand its vaccines business with a shot for hepatitis B and an experimental shingles inoculation. Sanofi will pay…
The French drugmaker will pay US$1.15 billion upfront with a commitment for potential milestones worth as much as US$450 million Sanofi agreed to buy UK biotech Vicebio for as…
France’s Sanofi has agreed to buy US-based Blueprint Medicines Corporation for up to US$9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a…
SANOFI said it will repurchase five billion euros (S$7 billion) of stock and grow profits more quickly this year as the drugmaker pivots away from consumer health to focus on fast-growing…
Doliprane is France’s best-selling drug and news that it could be partially sold to a foreign investor has prompted political concerns The French government needs guarantees from drugmaker…
